Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first mRNA ...
Moderna, the biotech that rose to fame for making one of the world’s first Covid-19 vaccines, has hit a new milestone: its ...
The Cambridge drugmaker’s mRNA vaccine for respiratory syncytial virus, or RSV, got the green light from the FDA on Friday.
The decision is a win for Moderna, which needs another revenue source amid plunging demand for its Covid vaccine, its only ...
The US Food and Drug Administration on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults - ...
You might have seen the news earlier this month: the U.S. has approved the first vaccine ... Drug to help prevent serious RSV illness in babies approved by Health Canada That decision may depend ...
The FDA is working to conclude its review by the end of May 2024. The Food and Drug Administration (FDA) has informed Moderna that its review of the Biologics License Application (BLA) for mRNA-1345, ...
Investors have put their hopes in Moderna's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine ... Is the FDA delay a setback for the biotech company?
Moderna’s waiting for the FDA ... vaccine portfolio, including several game-changing products. But news last week disappointed investors, who were expecting a regulatory decision on the RSV ...
Shares of Moderna, Inc. MRNA were down 4.4% on May 10 after the company announced that the FDA has delayed the review timeline for its mRNA-based, respiratory syncytial virus (RSV) vaccine ...